Eight years ago, the US FDA responded to outrage over the launch price of a newly approved pre-term labor drug, KV Pharmaceuticals’ Makena, by publicly announcing that it would – in effect – turn a blind eye to continued compounding of the ingredient (hydroxyprogesterone).
Importation To Address Drug Pricing? Just Do It – But Don’t Justify It
The idea of permitting importation of competitors to products like Daraprim has an undeniable appeal, and – unlike essentially every other idea on the table to deal with drug pricing – would actually address the singular example that helped kick off the current debate. But creating a legal framework to justify the action is very perilous for the industry overall.
